Identifai Genetics Limited (ASX:ID1)
Australia · Delayed Price · Currency is AUD 0.4800
-0.0050 (-1.03%)
Oct 23, 2026, 4:11 PM AEDT
Identifai Genetics Company Description
Identifai Genetics Limited provides prenatal genetic screening through the application of genome-wide sequencing and artificial intelligence in Israel, the United States, Hong Kong, China, and Australia.
The company’s product, Windrose, is a first-trimester non-invasive prenatal test that provides cfDNA-based fetal risk assessment for more than 280 clinically actionable genes, all from a single blood draw and without requiring a partner sample.
The company was founded in 2021 and is based in Subiaco, Australia.
Identifai Genetics Limited
| Country | Australia |
| Founded | 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| CEO | Eyal Miller |
Contact Details
Address: 295 Rokeby Road Subiaco, Washington 6008 Australia | |
| Phone | 61 8 6555 2950 |
| Website | identifai-genetics.com |
Stock Details
| Ticker Symbol | ID1 |
| Exchange | Australian Securities Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | AU0000488983 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Eyal Miller | Chief Executive Officer |
| Oren Tadmor | Head of Product and Co-founder |
| Gilad Magnazi | Chief Operating Officer |
| Prof. Noam Shomron Ph.D. | C.S.O |